G. Lewis

发表

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

E. Schelbert, Christopher A. Miller, G. Lewis, 2020, The New England journal of medicine.

Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF.

E. Schelbert, K. Kadler, Christopher A. Miller, 2020, Journal of the American College of Cardiology.

Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction

E. Schelbert, Christopher A. Miller, S. Dodd, 2022, Journal of Cardiovascular Translational Research.

Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction

E. Schelbert, Christopher A. Miller, A. Rosala-Hallas, 2022, The International Journal of Cardiovascular Imaging.

Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone

E. Schelbert, Christopher A. Miller, A. Rosala-Hallas, 2022, Journal of the American Heart Association.

Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial

P. Williamson, E. Schelbert, Christopher A. Miller, 2021, Nature Medicine.

Beyond Valvular Heart Disease.

Christopher A. Miller, S. Ray, G. Lewis, 2020, Journal of the American College of Cardiology.

Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial

S. Russell, S. Neubauer, P. Williamson, 2019, Cardiovascular Drugs and Therapy.

Predicting hospitalisation for heart failure and death in patients with, or at risk of, heart failure before first hospitalisation: a retrospective model development and external validation study

E. Schelbert, Christopher A. Miller, M. Schmitt, 2022, The Lancet. Digital health.

The utility of cardiovascular imaging in heart failure with preserved ejection fraction: diagnosis, biological classification and risk stratification

E. Schelbert, Christopher A. Miller, K. Pearce, 2020, Heart Failure Reviews.

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction.

E. Schelbert, T. McDonagh, Christopher A. Miller, 2017, Journal of the American College of Cardiology.

Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).

Javier A. Neyra, C. Lewis, Lawrence J. Fine, 2017, Circulation.

Considerations for Clinical Trials Targeting the Myocardial Interstitium.

M. Dweck, Christopher A. Miller, J. Naish, 2019, JACC. Cardiovascular imaging.

Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction

E. Schelbert, Christopher A. Miller, A. Rosala-Hallas, 2022, The International Journal of Cardiovascular Imaging.

Letter to the editor – Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension.

E. Schelbert, Christopher A. Miller, G. Lewis, 2017 .

The effect of 1.5 T cardiac magnetic resonance on human circulating leucocytes

E. Schelbert, Christopher A. Miller, D. Clark, 2018, European heart journal.

Outcome Measures in HFpEF Trials: Should We Refocus?

Christopher A. Miller, Gavin A. Lewis, G. Lewis, 2017, Journal of the American College of Cardiology.

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction.

E. Schelbert, T. McDonagh, Christopher A. Miller, 2017, Journal of the American College of Cardiology.

Treatment adherence in a randomised controlled trial of pirfenidone in HFpEF: determinants and impact on efficacy.

E. Schelbert, Christopher A. Miller, A. Rosala-Hallas, 2023, Journal of cardiac failure.